Development of a Short Telomere Zebrafish Model for Accelerated Aging Research and Antiaging Drug Screening
Aging Cell · 2025
DOI: 10.1111/acel.70007 ↗Kurz gefasst
Fachartikel in der Zeitschrift Aging Cell, 2025. Verfasst von David Hernández-Silva und 5 weiteren Autor:innen. Beteiligte Einrichtung: Grupo de Telomerasa, Cáncer y Envejecimiento, Hospital Clínico Universitario Virgen de la Arrixaca, Murcia, Spain. Hauptthemen laut MEDLINE: Zebrafish, Aging, Telomere, Telomere Shortening. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 44 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Instituto de Salud Carlos III (ISCIII) and co-funded by the European Union, Instituto de Salud Carlos III.
Abstract (Originalsprache)
Increased life expectancy is associated with a higher risk of age‐related diseases, which represent a major public health challenge. Animal models play a crucial role in aging research, enabling the study of diseases at the organism level and facilitating drug development and repurposing. Among these models, zebrafish stands out as an excellent in vivo system due to its unique characteristics. However, the longevity of zebrafish is a limitation for research, as it often takes too long to obtain results within a reasonable timeframe. To address this, we have developed a short telomere zebrafish line (ST2) with a premature aging phenotype during the larval stage. Although less extreme than the tert‐deficient G2 larvae, ST2 larvae exhibit reduced telomerase expression and activity, along with shortened telomeres. they also exhibit increased cellular senescence, apoptosis, and premature death. As a proof of concept, we evaluated the antiaging effects of two compounds: resveratrol (a polyphenol) and navitoclax (a senolytic). Our results confirm the antiaging properties of resveratrol, which improves telomere maintenance. However, navitoclax does not attenuate the ST2 phenotype. Taking advantage of the zebrafish larval model, this premature aging system provides a valuable platform for in vivo testing of rejuvenating molecules through drug screening, using telomere length or survival as a readout.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Grupo de Telomerasa, Cáncer y Envejecimiento, Hospital Clínico Universitario Virgen de la Arrixaca, Murcia, Spain.
- Instituto Murciano de Investigación Biosanitaria-Pascual Parrilla (IMIB-Pascual Parrilla), Murcia, Spain.
- Universidad Católica de Murcia (UCAM), Murcia, Spain.
- Centro de Investigación Biomédica en Red de Enfermedades Raras (CIBERER), Madrid, Spain.
ORCID-Profile: María L Cayuela, Francisca Alcaraz-Pérez
Förderung
- Instituto de Salud Carlos III (ISCIII) and co-funded by the European Union
- Instituto de Salud Carlos III
Zitieren
APA
Hernández-Silva, D., López-Abellán, M. D., Martínez-Navarro, F. J., García-Castillo, J., Cayuela, M. L., & Alcaraz-Pérez, F. (2025). Development of a Short Telomere Zebrafish Model for Accelerated Aging Research and Antiaging Drug Screening. Aging Cell. https://doi.org/10.1111/acel.70007
Vancouver
Hernández-Silva D, López-Abellán MD, Martínez-Navarro FJ, García-Castillo J, Cayuela ML, Alcaraz-Pérez F. Development of a Short Telomere Zebrafish Model for Accelerated Aging Research and Antiaging Drug Screening. Aging Cell. 2025. doi:10.1111/acel.70007
BibTeX
@article{HernndezSilva2025,
author = {Hernández-Silva, David and López-Abellán, María D and Martínez-Navarro, Francisco J and García-Castillo, Jesús and Cayuela, María L and Alcaraz-Pérez, Francisca},
title = {Development of a Short Telomere Zebrafish Model for Accelerated Aging Research and Antiaging Drug Screening},
journal = {Aging Cell},
year = {2025},
doi = {10.1111/acel.70007}
}
EUVIMED